Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.
|Published (Last):||5 January 2008|
|PDF File Size:||14.29 Mb|
|ePub File Size:||12.94 Mb|
|Price:||Free* [*Free Regsitration Required]|
Active treatment for graft-versus-host disease 6. Subjects are under 18 years old.
Medicinas para Quimioterapia – Nombres de Medicina
Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc.
The trial involves single site in the Member State concerned. For these items you should use the filters and not add them to your search terms in the l-aspargainasa field. EU Clinical Trials Register. Karnofsky or Lansky scores? Known allergy to any of the drugs used in the study. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.
Restricciones de tratamientos previos: Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7. Trials with results Trials without results Clear advanced search filters. Committee on Advanced therapies Adveesos has issued a classification for this product. The duration of this interval must be approved by the Onyx study medical monitor. Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.
Subjects must have l-aspaaginasa recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells.
Pneumonia AND sponsor name. Cancer AND drug name. Relapsed or Refractory Acute Lymphoblastic Leukemia.
Age 18 years or younger at the time of study treatment initiation. Title of the efectls for lay people, in easily understood, i. Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia.
l-asparaginasa efectos adversos pdf
IMP with orphan designation in the indication. How to search [pdf].
Adequate liver function, defined as both of the following: Clear advanced search filters. Review by the Competent Authority or Ethics Committee in the country concerned.
Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Trials with results Trials without results.
Both Female Only Male Only. The IMP has been designated in this indication as an orphan drug in the Community.
l-asparaginasa efectos adversos pdf – PDF Files
Combination product that includes a device, but does not involve an Advanced Therapy. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Subjects must have a serum creatinine level that is? Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial.
Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy? For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
Date on l-asparagnasa this record was first entered in the EudraCT database:.